AJ13--Pharmarcokinetics for Experimental Rheumatoid Arthritis treatment
Inactive on SAM.gov — responses were due 31 Jul 2026 · Unrestricted (full and open) · Department of Veterans Affairs (VA) · NAICS 112990 · Solicitation 36C24526Q0669
Following NAICS 112990? Get new solicitations in it by email as they post — no account needed.
A newer version of this notice has been posted. SAM.gov republished solicitation 36C24526Q0669 on 16 July 2026. This page is kept because it is a real record, but the current requirement, dates and attachments are on the latest version. Read the latest version →
What happened next
SAM.gov marked this notice inactive — responses were due 31 July 2026.
No award notice on SAM.gov yet. Not every award is posted there, so this does not mean it went unawarded.
Email me when the award is announced. One email, when SAM.gov posts the award notice. Not every award is posted there; if none appears within six months we'll tell you and stop. No account needed.
This one has closed. We'll email you when new NAICS 112990 (All Other Animal Production) solicitations post — the first email lists what is open right now, then at most once a week, only when something new posts. No account needed; unsubscribe in a click.
Description
SOURCES SOUGHT NOTICE Department of Veterans Affairs Network Contracting Office (NCO) 05 Title: A Joint Targeted Drug Delivery Approach for Arthritis Therapy Toxicity and Pharmacokinetics 1. Purpose This Sources Sought Notice is issued solely for market research in accordance with FAR Part 10. This is not a solicitation, and it does not commit the Government to issue a solicitation or make an award. The Department of Veterans Affairs (VA) seeks to identify qualified vendors capable of performing preclinical toxicology and pharmacokinetic (PK) studies on an experimental Rheumatoid Arthritis treatment involving peptide-displaying liposomes containing dexamethasone. 2. Requirement Overview The VA requires a contractor to perform GLP-compliant toxicity testing and GLP or non GLP pharmacokinetic studies in adult rats. These studies support advancement toward a future FDA Pre IND meeting for the patented joint-targeted liposomal delivery system developed under prior VA-funded research. 3. Summary of Required Services A. Toxicity Studies (GLP Required) Receive peptide displaying liposomes containing 150 mg dexamethasone, 80% encapsulation efficiency, with Certificate of Analysis. Conduct single dose intravenous toxicity testing in 20 32 rats (male and female). Record clinical observations, weight, and food intake over a 14 day period. Conduct blood testing for organ damage markers (liver, kidney, heart, muscle, etc.). Perform euthanasia, necropsy, and histopathology of major organs. B. Pharmacokinetic (PK) Studies (GLP or non GLP) Administer single IV doses to 12 24 rats (balanced sexes). Observe and weigh animals before and after dosing. Collect blood samples at 8 10 defined time points (10 min through 48 hours). Process plasma and store at 20°C. Perform chemical extraction and LC MS/MS quantification of dexamethasone and metabolite 6 hydroxydexamethasone (6OHDEX). Generate PK parameters (t½, Cmax, AUC, etc.). C. Final Deliverable Comprehensive written report summarizing toxicity, PK parameters, and analytical results. 4. Place of Performance Vendor s laboratory. Toxicology tasks must be performed under GLP. PK tasks may be performed under GLP or non GLP. 5. Period of Performance 1 year of service (if necessary) September 15, 2026 September 14, 2027. 6. Requested Information from Interested Vendors Please submit the following in your capability statement: Company name, address, point of contact, phone, and email. Unique Entity Identifier (UEI) and confirmation of active SAM.gov registration. Business size and socio economic status under NAICS 325412. Demonstrated technical capability and experience performing: GLP toxicology studies Rodent PK studies LC MS/MS analysis Histopathology and necropsy Relevant past performance for biomedical R&D or FDA preclinical support. Any additional information proving capability to meet the requirements. 7. Socio Economic Categories of Interest The VA encourages responses from: SDVOSB, VOSB, 8(a), HUBZone, WOSB, Small businesses, Large businesses 8. Point of Contact for Responses Contracting Officer: Robert O Keefe Jr. Email: robert.okeefejr@va.gov Please submit all capability statements directly to the Contracting Officer for review no later than (NLT) July 29, 2026 0900 Eastern Standard Time. Your email subject line should read: Response to Sources Sought Notice Approach for Arthritis Therapy Toxicity and Pharmacokinetics (NAICS 325412 / PSC AJ13) 9. Disclaimer Upon completion of Market Research, a Confidential Disclosure Agreement (CDA) will be required of selected vendors. The CDA must be fully executed before any proprietary information is released. Selected vendors will receive exclusive access to solicitation materials and proprietary documents once the CDA is completed. This Sources Sought Notice is for market research purposes only. Information received will assist the Government in shaping the acquisition strategy. This notice does not constitute a solicitation, does not request quotes, and does not obligate the Government to issue a solicitation or award a contract.
Version history
SAM.gov has posted 2 notices under solicitation 36C24526Q0669, oldest first.
FedSift reads the full solicitation package — every attachment — and pre-extracts the compliance matrix, evaluation factors, key risks, win themes and deal-breakers, each with a verbatim quote and the exact PDF page it came from. It scores the opportunity against your company profile, tells you whether to bid as prime or sub, and ranks teaming partners who could close your gaps.
Source: this notice on SAM.gov. FedSift republishes public federal procurement data and is not affiliated with the U.S. Government. Always confirm dates and requirements against SAM.gov before responding.
